Adjuvant erlotinib versus placebo in patients with stage IB-IIIA nonsmall-cell lung cancer (RADIANT): A randomized, double-blind, Phase III trial

Journal of Clinical Oncology

Volumn 33, Issue 34, 2015, Pages 4007-4014

  Kelly, Karen ^a   Altorki, Nasser K ^b   Eberhardt, Wilfried E E ^c   OBrien, Mary E R ^d   Spigel, David R ^e   Crinò, Lucio ^f   Tsai, Chun Ming ^g   Kim, Joo Hang ^h   Cho, Eun Kyung ⁱ   Hoffman, Philip C ^j   Orlov, Sergey V ^l   Serwatowski, Piotr ^m   Wang, Jiuzhou ^k   Foley, Margaret A ^k   Horan, Julie D ⁿ   Shepherd, Frances A ^o  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^g NATIONAL YANG MING UNIVERSITY   (Taiwan)

^h Yonsei University College of Medicine   (South Korea)

ⁱ Gachon University   (South Korea)

^j UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^k ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^l PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^m Specjalistyczny Szpital IM   (Poland)

ⁿ Novella Clinical   (United States)

^o UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PLACEBO; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; GENETICS; INTERNATIONAL COOPERATION; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; ERLOTINIB HYDROCHLORIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; YOUNG ADULT;

EID: 84948384227     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.8918     Document Type: Article

References (23)

1. Arriagada R, Auperin A, Burdett S, et al: Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two meta-Analyses of individual patient data. Lancet 375:1267-1277, 2010
2. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004
3. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005
4. Strauss GM, Herndon JE 2nd, Maddaus MA, et al: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26:5043-5051, 2008
5. Douillard JY, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 7:719-727, 2006
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
7. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529, 2010
8. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
9. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005
10. Hirsch FR, Varella-Garcia M, Bunn PA Jr., et al: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer. J Clin Oncol 24:5034-5042, 2006
11. Brugger W, Triller N, Blasinska-Morawiec M, et al: Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebocontrolled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29:4113-4120, 2011
12. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111:1710-1717, 1997
13. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
14. National Cancer Institute: Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic-Applications/docs/ctcaev3.pdf
15. Zhu CQ, da Cunha Santos G, Ding K, et al: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26:4268-4275, 2008
16. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008
17. Janjigian YY, Park BJ, Zakowski MF, et al: Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol 6:569-575, 2011
18. Pennell NA, Neal JW, Chaft JE, et al: SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. J Clin Oncol 32:480s, 2014 (abstr 7514)
19. Goss GD, O'Callaghan C, Lorimer I, et al: Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study. J Clin Oncol 31:3320-3326, 2013
20. Kelly K, Chansky K, Gaspar LE, et al: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:2450-2456, 2008
21. Yeo WL, Riely GJ, Yeap BY, et al: Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol 5:1048-1053, 2010
22. Nakahara Y, Hosomi Y, Yamada K, et al: A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non-small cell lung cancer (NSCLC) with activating mutation of epidermal growth factor receptor (EGFR): Thoracic Oncology Research Group (TORG) 0911. J Clin Oncol 32:525s, 2014 (abstr 8080)
23. Lampson BL, Santos A, Janne PA, et al: Reduced-dose versus full-dose erlotinib for advanced EGFR-mutant non-small cell lung carcinoma (NSCLC): A retrospective analysis. J Clin Oncol 33, 2015 (abstr 8074)